Victory Capital Management Inc. decreased its stake in NxStage Medical, Inc. (NASDAQ:NXTM) by 22.8% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 1,091,649 shares of the medical device company’s stock after selling 322,450 shares during the period. Victory Capital Management Inc. owned about 1.66% of NxStage Medical worth $27,368,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the company. FMR LLC boosted its position in NxStage Medical by 1.9% in the first quarter. FMR LLC now owns 7,482,201 shares of the medical device company’s stock valued at $200,747,000 after buying an additional 137,399 shares during the last quarter. Vanguard Group Inc. boosted its position in NxStage Medical by 8.5% in the first quarter. Vanguard Group Inc. now owns 5,273,762 shares of the medical device company’s stock valued at $141,495,000 after buying an additional 412,233 shares during the last quarter. BlackRock Inc. boosted its position in NxStage Medical by 38,360.4% in the first quarter. BlackRock Inc. now owns 4,413,326 shares of the medical device company’s stock valued at $118,408,000 after buying an additional 4,401,851 shares during the last quarter. Eagle Asset Management Inc. purchased a new position in NxStage Medical during the first quarter valued at $54,558,000. Finally, William Blair Investment Management LLC boosted its position in NxStage Medical by 491.6% in the second quarter. William Blair Investment Management LLC now owns 1,959,318 shares of the medical device company’s stock valued at $49,120,000 after buying an additional 1,628,114 shares during the last quarter. Hedge funds and other institutional investors own 93.20% of the company’s stock.

NxStage Medical, Inc. (NASDAQ NXTM) opened at 27.97 on Friday. The stock’s 50 day moving average is $26.55 and its 200 day moving average is $25.99. The stock’s market capitalization is $1.85 billion. NxStage Medical, Inc. has a 12-month low of $20.45 and a 12-month high of $30.80.

NxStage Medical (NASDAQ:NXTM) last released its earnings results on Monday, August 7th. The medical device company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03). The business had revenue of $92.20 million during the quarter, compared to the consensus estimate of $96.47 million. NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.03) earnings per share. Analysts forecast that NxStage Medical, Inc. will post ($0.04) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/02/nxstage-medical-inc-nxtm-shares-sold-by-victory-capital-management-inc.html.

NXTM has been the topic of several research analyst reports. Craig Hallum cut shares of NxStage Medical from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. BTIG Research reiterated a “buy” rating and set a $27.00 price objective on shares of NxStage Medical in a research report on Wednesday, May 10th. Jefferies Group LLC lowered their price objective on shares of NxStage Medical from $38.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, May 10th. Stephens cut shares of NxStage Medical from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $33.00 to $30.00 in a research report on Wednesday, August 9th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $32.00 price objective on shares of NxStage Medical in a research report on Monday, May 8th. One investment analyst has rated the stock with a sell rating and nine have assigned a hold rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $30.25.

In related news, SVP Matthew W. Towse sold 4,300 shares of the firm’s stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $23.29, for a total value of $100,147.00. Following the completion of the transaction, the senior vice president now owns 29,637 shares of the company’s stock, valued at $690,245.73. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, President Joseph E. Turk, Jr. sold 24,000 shares of the firm’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $29.64, for a total transaction of $711,360.00. Following the completion of the transaction, the president now directly owns 82,903 shares of the company’s stock, valued at approximately $2,457,244.92. The disclosure for this sale can be found here. In the last ninety days, insiders sold 53,900 shares of company stock valued at $1,463,316. 4.70% of the stock is owned by insiders.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Stock Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related stocks with our FREE daily email newsletter.